2022-05-19

MLO Online: COVID-19’s impact on testing practices for STIs

James Walker

The decrease in STI testing seen during the first few months of the pandemic resulted in low reporting of disease. As patients get back to doctors’ offices to catch-up on delayed screenings, STI testing demand is now on the rise. Laboratories are faced with higher volumes of tests to process with fewer staff members and shortages of laboratory consumables.

James Walker, Global Business Leader of Molecular Diagnostics & Women’s Health and Cancer at BD, shares his insights into the challenges faced by labs and the steps labs can take to diagnose patients with greater accuracy and efficiency.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

Chris Beddard, Vice President, U.S. Marketing, Integrated Diagnostic Solutions at BD
Cervical Cancer | News & Updates
NJBIZ Conversations: Chris Beddard
BD blog: The future of cervical cancer screening: More genotypes means more precise care
Cervical Cancer | News & Updates
BD blog: The future of cervical cancer screening: More genotypes means more precise care
Modern Healthcare: How is extended genotyping shaping the future of cervical cancer screening?
Cervical Cancer | News & Updates
Modern Healthcare: How is extended genotyping shaping the future of cervical cancer screening?